biospectrumSeptember 10, 2018
Tag: Agios , Celgene , partnership , cancer
Agios Pharmaceuticals and Celgene have mutually agreed to terminate their collaboration and license agreement inked on April 27, 2015, to develop and commercialize products containing pan-IDH inhibitor AG-881.
Global rights will revert back to Agios. Celgene will be eligible to receive low single-digit royalties on global net sales and both companies will split certain global development costs until year-end.
For a specific time period (undisclosed), Celgene and its affiliates will be prohibited from developing, manufacturing or commercializing any product containing isocitrate dehydrogenase 1 (IDH1) at specific levels of binding for any indication. Agios will be prohibited from developing, manufacturing or commercializing AG-881 in blood cancers.
The termination comes three months after Agios presented its first data from an ongoing Phase I study (NCT02481154) assessing AG-881 as a single agent in advanced glioma and other solid tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting.
-----------------------------------------------------------------------------
Editor's Note:
To apply for becoming a contributor of En-CPhI.cn,
welcome to send your CV and sample works to us,
Email: Julia.Zhang@ubmsinoexpo.com.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: